Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.30 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10439558 | 0.81 | CYP1A2 (0.44) | CYP11B1CYP11B2CYP1A2CYP2D6HIF1A | |
| SCHEMBL643809 | 0.79 | CYP11B1 (0.37) | CYP11B1CYP11B2CYP1A2CYP2D6HIF1A | |
| SCHEMBL3855448 | 0.77 | NSD3 (0.38) | CYP11B1CYP11B2ALDH1A1HPGDKMT2A | |
| SCHEMBL7310245 | 0.75 | CYP11B1 (0.34) | CYP11B1CYP11B2CYP1A2CYP2D6HIF1A | |
| SCHEMBL12907351 | 0.75 | CYP3A4 (0.36) | CYP11B1CYP11B2CYP1A2CYP2D6HIF1A | |
| SCHEMBL312495 | 0.75 | KDM4C (0.39) | CYP11B1CYP11B2ALDH1A1KMT2AMEN1 | |
| SCHEMBL9585649 | 0.75 | TAAR1 (0.35) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL846 | 0.75 | CYP11B1 (0.34) | CYP11B1CYP11B2CYP1A2CYP2D6HIF1A | |
| SCHEMBL923644 | 0.73 | LMNA (0.37) | CYP11B1CYP11B2CYP1A2ALDH1A1HPGD | |
| SCHEMBL12907335 | 0.73 | CYP11B1 (0.37) | CYP11B1CYP11B2CYP1A2CYP2D6HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890139-B2 | CYP17 inhibitors/antiandrogens | ORION CORPORATION (FI) | 2018-02-13 | — | — | US | disclosed |
| US-20160130254-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | ORION CORPORATION (FI) | 2016-05-12 | — | — | US | disclosed |
| EP-3008042-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | Orion Corporation (FI) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014202827-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | ORION CORPORATION (FI) | 2014-12-24 | — | — | WO | disclosed |
| US-8258167-B2 | Naphthylmethylimidizoles as therapeutic agents | ALLERGAN, INC (US) | 2012-09-04 | — | — | US | disclosed |
| US-8119807-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8013169-B2 | Naphthylmethylimidizoles as therapeutic agents | ALLERGAN, INC (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2296655-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2296648-A1 | NAPHTHYLMETHYLIMIDIZOLES FOR THE TREATMENT OF STRESS URINARY INCONTINENCE | Allergan, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1618120-A2 | NOVEL KETOLIDE DERIVATIVES | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050153905-A1 | Novel ketolide derivatives | CHIRON CORPORATION (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004096823-A2 | NOVEL KETOLIDE DERIVATIVES | CHIRON CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096822-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| EP-1404693-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003004509-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| US-6080870-A | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors | MERCK & CO., INC. (US) | 2000-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | CYP11B1 262/4885CYP11B2 376/4885CYP1A2 383/4885 |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | CYP11B1 98/4885CYP11B2 117/4885CYP1A2 146/4885 |
| US-20050153905-A1 | Novel ketolide derivatives | KHK, CYP51A1, SI | CYP11B1 207/4885CYP11B2 320/4885CYP1A2 398/4885 |
| US-20160130254-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | CYP17A1, CYP19A1, CYP21A2 | CYP11B1 6/4885CYP11B2 9/4885CYP1A2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.